BRIAN PERRY: Open Payments
NPI 1992254486 · PARAGOULD, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$679 in 23 payments from 9 companies in 2025. Trend: 2023 $726 · 2024 $712 · 2025 $679
Food & beverage: $679
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 6 | $237 |
| Otsuka America Pharmaceutical, Inc. | 3 | $122 |
| Alkermes, Inc. | 4 | $108 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| E.R. Squibb & Sons, L.L.C. | 2 | $46 |
| Neurocrine BioSciences, Inc. | 2 | $42 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| ABBVIE INC. | 1 | $15 |
Products named: Auvelity, ABILIFY MAINTENA, CAPLYTA, ARISTADA, COBENFY, INGREZZA, LYBALVI, SPRAVATO.
Industry payments across AR — which companies pay providers there.
